ADGM on Nasdaq
Adagio Medical Holdings, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with QTREX Quantum Ltd., PULSE BIOSCIENCES, INC. or Bluejay Diagnostics, Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 |
|---|---|
| Revenue | $0 |
| Cost of revenue | $684.0K |
| Research and development | $10.6M |
| Selling, general, and administrative | $10.6M |
| Impairment - Goodwill | $0 |
| Total cost of revenue and operating expenses | $21.9M |
| Loss from operations | -$21.9M |
| Interest expense | -$2.9M |
| Interest income | $477.0K |
| Other (expense) income, net | $195.0K |
| Total other (loss) income, net | -$3.2M |
| Net loss | -$25.1M |
| Foreign currency translation adjustment | -$100.0K |
| Comprehensive loss | -$25.2M |
| Basic net loss per share (in dollars per share) | -$1.51 |
| Diluted net loss per share (in dollars per share) | -$1.51 |
| Weighted-average shares outstanding - Basic (in shares) | 16.6M shares |
| Weighted-average shares outstanding - Diluted (in shares) | 16.6M shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2024-07-31 |
|---|---|---|---|
| Cash and cash equivalents | $17.1M | $20.6M | |
| Accounts receivable, net | $35.0K | ||
| Inventory, net | $1.7M | $2.6M | |
| Prepaid expenses | $989.0K | $1.9M | |
| Other current assets | $316.0K | $222.0K | |
| Total current assets | $20.1M | $25.3M | |
| Property and equipment, net | $1.5M | $2.0M | |
| Right-of-use assets, net | $697.0K | $188.0K | |
| Intangible assets, net | $7.0M | $7.0M | |
| Goodwill, net | $14.0M | $14.0M | |
| Other assets | $3.0K | $14.0K | |
| Total assets | $43.3M | $48.4M | |
| Accounts payable | $1.1M | $2.8M | |
| Accrued liabilities | $7.0M | $3.7M | |
| Operating lease liabilities, current | $155.0K | $143.0K | |
| Other accrued liabilities | $1.1M | ||
| Total current liabilities | $8.2M | $7.8M | |
| Operating lease liabilities, long-term | $563.0K | $46.0K | |
| Convertible notes payable, net | $21.0M | $16.1M | |
| Warrant liabilities | $132.0K | $152.0K | |
| Deferred tax liabilities, net | $883.0K | $883.0K | |
| Other long-term liabilities | $3.6M | ||
| Total liabilities | $30.9M | $28.5M | |
| Common stock, $0.0001 par value; 210,000,000 shares authorized at December 31, 2025 and December 31, 2024; 22,210,459 and 15,198,232 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $2.0K | $2.0K | |
| Additional paid-in capital | $108.1M | $90.5M | |
| Accumulated other comprehensive (loss) income | -$99.0K | $1.0K | |
| Accumulated deficit | -$95.6M | -$70.6M | |
| Total stockholders' equity | $12.4M | $19.9M | $73.0M |
| Total liabilities and stockholders' equity | $43.3M | $48.4M | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | $0.00 |
| Common stock, shares authorized | 210.0M shares | 210.0M shares | 6.6M shares |
| Common stock, shares issued | 22.2M shares | 15.2M shares | 786.5K shares |
| Common stock, shares outstanding | 22.2M shares | 15.2M shares | 779.9K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 |
|---|---|
| Net loss | -$25.1M |
| Depreciation and amortization | $970.0K |
| Stock-based compensation | $1.5M |
| Impairment - Goodwill | $0 |
| Change in fair value of convertible notes payable | $980.0K |
| Change in fair value of warrant liabilities | -$20.0K |
| Accounts receivable, net | $38.0K |
| Inventory, net | $931.0K |
| Prepaid expenses and other current assets | $867.0K |
| Accounts payable | -$1.8M |
| Accrued liabilities | $3.3M |
| Other accrued liabilities | $2.9M |
| Operating lease liabilities | $20.0K |
| Other long-term liabilities | -$3.6M |
| Net cash used in operating activities | -$19.0M |
| Purchases of property and equipment | -$374.0K |
| Net cash used in investing activities | -$374.0K |
| Proceeds from the issuance of common shares, pre-funded warrants and warrants, net of $2,865 issuance costs | $16.1M |
| Net cash provided by financing activities | $16.1M |
| Effect of foreign currency translation on cash and cash equivalents | -$227.0K |
| Net change in cash and cash equivalents | -$3.5M |
| Issuance of common shares, pre-funded warrants and warrants issuance costs | $2.9M |
Former names
- Aja Holdco, Inc.Feb 14, 2024 to Aug 1, 20242
Recent filings
- Oct 13, 2026DEF 14A
- Oct 13, 20264
- Oct 1, 2026PRE 14A
- Oct 1, 20268-K
- Sep 23, 20268-K
- Aug 14, 20268-K
- Aug 14, 2026SCHEDULE 13G/A
- Aug 13, 20268-K
- Aug 12, 20264
- Aug 12, 20264
- Aug 12, 20264
- Aug 12, 20264
- Aug 12, 20264
- Aug 12, 20264
- Aug 11, 20268-K
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6